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Abstract
Background: To determine if patients without dobutamine induced left ventricular wall motion
abnormalities (WMA) but an increased LV end-diastolic wall thickness (EDWT) exhibit a favorable
cardiac prognosis.
Results: Between 1999 and 2001, 175 patients underwent a dobutamine stress cardiovascular
magnetic resonance (DCMR) procedure utilizing gradient-echo cines. Participants had a LV ejection
fraction >55% without evidence of an inducible WMA during peak dobutamine/atropine stress.
After an average of 5.5 years, all participants were contacted and medical records were reviewed
to determine the post-DCMR occurrence of cardiac death, myocardial infarction (MI), and unstable
angina (USA) or congestive heart failure (CHF) warranting hospitalization.
In a multivariate analysis, that took into account Framingham and other risk factors associated with
cardiac events, a cine gradient-echo derived LV EDWT ≥12 mm was associated independently with
an increase in cardiac death and MI (HR 6.0, p = 0.0016), and the combined end point of MI, cardiac
death, and USA or CHF warranting hospitalization (HR 3.0, p = 0.0005).
Conclusion: Similar to echocardiography, CMR measures of increased LV wall thickness should
be considered a risk factor for cardiac events in individuals receiving negative reports of inducible
ischemia after dobutamine stress. Additional prognostic studies of the importance of LV wall
thickness and mass measured with steady-state free precession techniques are warranted.
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Background
Left ventricular (LV) wall motion abnormalities (WMA)
induced during intravenous dobutamine are associated
with flow limiting epicardial coronary artery stenoses, and
predict future cardiac events including myocardial infarc-
tion (MI) and cardiac death [1-4]. Typically, if resting LV
end-diastolic wall thickness (EDWT) is normal, the
absence of dobutamine inducible WMA identifies a group
of individuals with a low risk of experiencing future car-
diac events [5,6]. Importantly however, in individuals
with increased resting LV EDWT, the sensitivity of dob-
utamine induced LV WMA for identifying flow limiting
epicardial stenoses is low (36%) [7]. Also, data from
Framingham have shown that increased LV EDWT itself is
an independent predictor of cardiac events [8]. To date, it
remains uncertain whether individuals with increased
resting LV EDWT and an absence of inducible LV WMA
during intravenous dobutamine remain at a relatively low
risk of developing a future cardiac event.
This study was performed to determine if the absence of
inducible WMA during intravenous dobutamine would
be associated with a favorable cardiac prognosis regardless
of resting LV EDWT. To address this question, we meas-
ured LV EDWT and performed extensive follow-up on
individuals undergoing dobutamine stress cardiovascular
magnetic resonance (DCMR) examinations with cine
white blood fast-gradient echo techniques.
Methods
Population and Study Design
The study complies with the Declaration of Helsinki, and
was approved by the Institutional Review Board at the
Wake Forest University School of Medicine. All patients
gave both verbal (for performing follow-up question-
naire) and written (for CMR and later for review of medi-
cal records) informed consent. Between 1997 and 2001,
175 consecutive participants with a LV ejection fraction
>55%, and no inducible LV WMA indicative of ischemia
in any of 17 myocardial segments during DCMR were
enrolled in the study. After DCMR, participants blinded to
DCMR test results performed the outcomes analysis.
Dobutamine/Atropine Cardiovascular Magnetic 
Resonance
As previously described [3,5], images were obtained on a
Horizon 1.5T whole-body imaging system (General Elec-
tric Medical Systems) using cine white blood spoiled gra-
dient-echo imaging with a 256 × 128 matrix, a 3548-cm
field of view, a 4-ms echo time, a 10-ms repetition time, a
20-degree flip angle, an 8-mm slice thickness, a 40-ms
temporal resolution, and 8 to 12 second periods of breath
holding. Each of the patients received atropine if they
were unable to obtain 80% maximum predicted heart rate
for age (n = 95). Findings of this heart rate response have
been shown at our institution to be 83% sensitive and
83% specific for identifying >50% coronary arterial lumi-
nal narrowings during dobutamine/atropine stress, and
have been shown to forecast future cardiac events [3,5].
At rest and during graded doses of dobutamine/atropine
stress, LV wall motion was confirmed as normal across all
17 myocardial segments [5]. The resting LV ejection frac-
tion was measured using a biplane area-length technique
[9]. According to previously published techniques, the
posterior and septal wall thicknesses were measured at the
level of the LV minor dimension, at the mitral chordae
level using the end-diastolic, left ventricular 3-chamber
(equivalent to transthoracic echocardiography parasternal
long-axis) view (Figure 1) [10]. At the time of testing, the
occurrence of a prior Q-wave myocardial infarction [11],
and the presence of cardiac risk factors [including a his-
tory of diabetes [12], smoking, coronary revasculariza-
tion, elevated total cholesterol [13], and hypertension
[14] were recorded.
Outcomes
Within 7 years of the DCMR exam, each participant was
contacted to determine the post-procedure occurrence of
cardiac events. All persons were contacted initially by
phone or personal interview. If deceased, the next of kin
was contacted. Questions were administered to identify
the possibility of myocardial infarction (MI), unstable
angina (USA) or congestive heart failure (CHF). Any
In accordance with the American Society of Echocardiogra- phy, posterior (green line) and septal (red line) left ventricu- lar wall thickness was measured in the left ventricular long  axis view at end diastole at approximately the level of the  mitral valve leaflet tips (LV = left ventricle; LA = left atrium;  and Ao = aorta) Figure 1
In accordance with the American Society of Echocar-
diography, posterior (green line) and septal (red line) 
left ventricular wall thickness was measured in the 
left ventricular long axis view at end diastole at 
approximately the level of the mitral valve leaflet 
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change in physical state, medical condition, or medica-
tionwas confirmed in all cases by review of the partici-
pant's medical records. If an event was suspected or
identified during contact with the participant, medical
records from the site of the event were obtained and con-
firmation of the event was determined according to data
collected from the medical record. Established, published
criteria were utilized to define events. Hard events were
defined as cardiac death (death in the presenceof acute
MI, significant cardiac arrhythmia, or refractory CHF [15],
or MI (angina of >30 minutes durationand either ≥ 2 mm
ST segment elevation in 2 consecutive ECG leadsor a rise
in cardiac enzymes including creatine kinase level MB
fraction cardiac troponin-I above normal limits) [16].
Electrocardiographic, enzymatic, or autopsy data were
used tosubstantiate cardiac mortality. Any events were
defined as hard events and/or USA, or CHF warranting
hospital admission. In the case of 2 simultaneouscardiac
events, the worst event was chosen (cardiac death>MI>
USA>CHF).
Statistical Analysis
After all records were obtained, a statistical analysis was
conducted using SAS 9.1 (SAS Institute, Cary, NC) for
Windows. Based on previously published criteria, partici-
pants were dichotomized into those with a LV EDWT < or
≥12 mm [15]. In this study, we determined LV EDWT in
the septum, posterior wall, and the average of the two. The
average LV EDWT of the septal and posterior walls served
as the primary outcome measure. All grouped data were
expressed as mean ± SD. Independent predictors of events
were identified using univariate and multivariate Cox pro-
portional hazards regression models. The risk of a given
variable was expressed by a hazard ratio (HR) with corre-
sponding 95% CIs. A variable was considered significant
if the null hypothesis of no contribution could be rejected
at a probability value of <0.05. The probability of the pres-
ence or absence of hard events as a function of follow-up
duration was estimated by the Kaplan-Meier method and
compared between groups by use of the log-rank test.
Unadjusted, Framingham adjusted, and additional car-
diac MI risk factor adjusted Cox proportional hazard
regression models were used to predict cardiac events.
To determine the intra observer variability for measuring
LV EDWT, a randomly selected sample of 20 participants
was analyzed twice separated by 1 year. To determine inter
observer agreement in measures of LV EDWT, this same
sample from 20 participants was analyzed by a separate
individual. In both the intra and inter observer compari-
sons, repeat assessments were performed in an unpaired
fashion blinded to the results of prior analyses.
The authors had full access to the data and take responsi-
bility for its integrity.
Results
Contact was made with all 175 patients; their clinical data
are displayed in Table 1. Those with an average (septal
and posterior wall) LV EDWT ≥12 mm were older, and
exhibited more prior CAD, hypertension, diabetes, and
lung disease. Overall, the amount of dobutamine admin-
istered was 30 ± 10 μg/kg/min and did not differ between
those with and without a LV EDWT < or ≥12 mm. Rest and
stress hemodynamic assessments at the time of DCMR
stress were similar for those with or without LV EDWT <
or ≥12 mm (Table 2).
Over the 5.5 average years of follow-up, the rate of hard
events was 8.4% (Table 3). The 5.5 year hard event rate
was 3.2% for the patients with a LV EDWT <12 mm com-
pared to 20.3% for those with a LV EDWT ≥12 mm. The
EDWT for the posterior wall averaged 12 ± 3 mm in par-
ticipants with no events, and 14 ± 3 mm in participants
with any events (p < 0.001). Similarly, the septal wall
thickness in patients without events was 12 ± 3 mm com-
pared to 14 ± 4 mm for those with any events (p < 0.001).
The septal and posterior wall thickness among the partic-
ipants were highly correlated (r = 0.76, p = 0.001). There
was no difference in the predictive accuracy of the septal,
posterior, or combined average of the wall thickness for
identifying those at risk of future cardiac events.
The proportion of participants free of both hard and any
cardiac events is shown in Figure 2. A LV EDWT ≥12 mm
was predictive of both any and hard events in a) the unad-
justed model, b) the Framingham risk factor adjusted
model, and c) after adjustment for factors associated with
CAD, MI, and cardiac events (Figure 3 and Table 4). We
also performed analyses treating LV EDWT as a continu-
ous, as opposed to dichotomous (< or ≥12 mm thick) var-
iable. Using the proportional hazard wall thickness as a
continuous variable demonstrated a significant trend of
increasing risk of hard events (p = 0.004) and any events
(p = 0.001) with increasing LV EDWT.
The intra observer correlation of LV EDWT was 0.73, and
the inter observer assessment of LV EDWT was 0.77.
Discussion
Prior studies have found that increased LV EDWT during
a dobutamine stress test is associated with a decreased
sensitivity for detecting flow limiting coronary arterial
luminal narrowings detected with contrast coronary angi-
ography [7]. Other studies have identified an association
between the presence of LV hypertrophy or increased LV
EDWT and an adverse cardiac prognosis [8,17-19]. In
many countries, dobutamine stress echocardiography is
performed widely for individuals suspected to have or
possessing coronary arteriosclerosis, MI, or CHF. Individ-
uals without inducible LV WMA are ascribed a favorableJournal of Cardiovascular Magnetic Resonance 2009, 11:25 http://www.jcmr-online.com/content/11/1/25
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Table 1: Demographic data
LV EDWT LV EDWT p-value
Total ≤12 mm >12 mm
n = 175 n = 98 n = 77
Patient Characteristics
Age (yrs) 69 (± 12) 65 (± 15) 71 (± 10) 0.013
Gender Women, Men 102 73.0 63 35.0 39 38.0 0.07
Weight (kg) 92.2 (± 23.4) 90.6 (± 23.0) 94.3 (± 23.7) 0.32
BSA (m2) 2.3 (± 0.7) 2.1 (± 0.7) 2.4 (± 0.8) 0.56
Wall Thickness 12.3 (± 3.1) 9.2 (± 0.8) 16.0 (± 2.4) 0.0001
Historical Information
Prior CAD 81 (50.0%) 41 (41.8%) 40 (51.9%) 0.190
Prior Revascularization 28 (16.0%) 10 (10.2%) 18 (23.4%) 0.018
Hypertension 112 (64.0%) 52 (53.1%) 60 (77.9%) 0.0006
Diabetes Melitus 51 (29.1%) 23 (23.5%) 28 (36.4%) 0.063
Hyperlipidemia 89 (50.9%) 46 (46.9%) 43 (55.8%) 0.240
Smoking 64 (36.6%) 31 (31.6%) 33 (42.9%) 0.130
Asthma/COPD 39 (22.3%) 16 (16.3%) 23 (29.9%) 0.033
Medications
Digoxin 9 (5.1%) 6 (6.1%) 3 (3.9%) 0.51
Vasodilator 14 (8.0%) 7 (7.1%) 28 (36.4%) 0.64
Diuretic 60 (34.3%) 32 (32.7%) 28 (36.4%) 0.61
Beta Blocker 54 (30.9%) 23 (23.5%) 31 (40.3%) 0.017
Calcium Antagonist 32 (18.3%) 13 (13.3%) 19 (24.7%) 0.053
ASA 82 (46.9%) 43 (43.9%) 39 (50.6%) 0.38
Nitrate 45 (25.7%) 20 (20.4%) 25 (32.5%) 0.071
ACE Inhibitor 39 (22.3%) 16 (16.3%) 23 (29.9%) 0.033
Anti-Coagulation 15 (8.6%) 4 (4.1%) 11 (14.3%) 0.017
Statin 65 (37.1%) 28 (28.6%) 37 (48.1%) 0.0079
Abbreviations: ACE, angiotensin converting enzyme; ASA, aspirin, BSA; body surface area; CAD, coronary artery disease; CHF, congestive heart 
failure; COPD, chronic obstructive airways disease, LV EDWT, left ventricular end-diastolic wall thickness.
Table 2: Hemodynamic data
Hemodynamic Data Total LV EDWT LV EDWT p-value
≤12 mm >12 mm
Rest
Heart Rate (bpm) 73 ± 18 73 ± 17 73 ± 20 0.99
Systolic Blood Pressure (mmHg) 136 ± 38 134 ± 35 138 ± 43 0.48
Diastolic Blood Pressure (mmHg) 76 ± 22 75 ± 20 77 ± 25 0.48
Stress
Heart Rate (bpm) 129 ± 28 131 ± 30 126 ± 27 0.30
Systolic Blood Pressure (mmHg) 143 ± 42 143 ± 40 143 ± 47 0.93
Diastolic Blood Pressure (mmHg) 74 ± 24 73 ± 21 76 ± 27 0.59
Abbreviations: bpm, blood pressure measure; mmHg, millimeters of mercury; LV EDWT, left ventricular end-diastolic wall thickness.Journal of Cardiovascular Magnetic Resonance 2009, 11:25 http://www.jcmr-online.com/content/11/1/25
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prognosis, and thus often are not referred for aggressive
risk management. Given the prevalence of risk factors
such as hypertension, and an abnormal increase in LV
EDWT in these patients, we felt it important to determine
if the favorable prognosis in patients with a negative dob-
utamine stress test and a normal resting LV EDWT would
occur in patients with a negative dobutamine stress test
and an increase in resting LV EDWT. Our results indicate
that in the absence of inducible LV WMA during intrave-
nous dobutamine, either an average, a septal, or a poste-
rior LV EDWT ≥12 mm measured in the 3-chamber
(similar to echocardiographic parasternal long-axis view)
using gradient-echo techniques was associated independ-
ently with future adverse cardiovascular events (Figure 2).
Four possibilities could explain our results. First, with
dobutamine stress echocardiography, previous investiga-
tors have noted an inability to visualize all myocardial
wall segments during cardiac stress testing procedures
[3,5], and thus one potentially can miss visualization of
an inducible LV wall motion abnormality indicative of
ischemia (a known risk factor for cardiac events) during
intravenous dobutamine. For this reason, we utilized
CMR because of previously reported high image quality
and ability to assess both LV EDWT and WMA throughout
the course of a dobutamine infusion [3-6]. In the current
study, LV wall motion was visualized throughout the
course of testing in all segments for all participants; and
thus, inadvertently missing a stress induced LV wall
motion abnormality due to suboptimal image quality is
not felt to be the cause of the poor prognosis observed
within the participants of the current study.
Second, as shown in Table 1, the participants that experi-
enced an increased incidence of cardiovascular events also
exhibited many illnesses or clinical conditions, including
hypertension, advanced age, prior coronary artery disease
and diabetes, that have been associated previously with an
adverse cardiac prognosis [11-14]. Importantly however,
Table 3: Table of events
Total LV EDWT LV EDWT p-value
≤12 mm >12 mm
Hard Events 16 (8.4%) 3 (3.2%) 13 (20.3%) 0.0015
Cardiac Deaths 12 (6.4%) 3 (3.2%) 9 (13.2%) 0.025
Myocardial Infarction 4 (2.2%) 0 (0.0%) 4 (5.5%) 0.022
Non Hard Event Hospital Admissions 26 (12%) 12 (12.2%) 14 (22.2%) 0.37
Congestive Heart Failure 2 (1.1%) 0 (0.0%) 2 (2.7%) 0.11
Unstable-Angina 24 (13.1%) 12 (12.2%) 12 (15.6%) 0.4
Abbreviation: LV EDWT, left ventricular end-diastolic wall thickness
Kaplan-Meier survival curves for participants free from any  cardiac event (Panel A), or a hard cardiac event (Panel B) Figure 2
Kaplan-Meier survival curves for participants free 
from any cardiac event (Panel A), or a hard cardiac 
event (Panel B). Graphs for individuals with and without 
LV end-diastolic wall thickness >12 mm are shown.Journal of Cardiovascular Magnetic Resonance 2009, 11:25 http://www.jcmr-online.com/content/11/1/25
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after serial adjustments utilizing multivariate models that
included Framingham risk factors (age, gender, smoking,
hypertension, elevated cholesterol) and other clinical
conditions associated with adverse cardiac events, the
presence of a LV EDWT ≥12 mm was a predictor of an
adverse cardiac prognosis independent of the association
that our participants may have had with known risk fac-
tors for adverse cardiac events. Thus, these analyses sup-
port the notion that LV EDWT is an independent risk
factor, and that the poor prognosis identified in our par-
ticipants was not due to confounding from a variable
already known to be associated with adverse cardiovascu-
lar risk.
Third, Smart, et al [7], have shown that in individuals with
increased LV EDWT, the utility of dobutamine induced
WMA for identifying inducible ischemia in patients with
single vessel coronary artery disease is substantially
reduced [7]. This is thought secondary to enhanced epi-
cardial contraction in the thickened wall that can over-
come the loss of contraction that may occur as
endocardial tissue becomes ischemic during stress [7]. It
Hazard ratios from multivariate analyses for average LV end-diastolic wall thickness >12 mm for any (Panel A) and hard (Panel  B) cardiac events Figure 3
Hazard ratios from multivariate analyses for average LV end-diastolic wall thickness >12 mm for any (Panel A) 
and hard (Panel B) cardiac events. As shown, the top row represents the unadjusted Cox proportional hazard model, the 
second row represents the Cox proportional hazard model adjusted for Framingham risk factors, and the last row represents 
the Cox proportional hazard model adjusted for Framingham risk factors and other factors associated with cardiac events.Journal of Cardiovascular Magnetic Resonance 2009, 11:25 http://www.jcmr-online.com/content/11/1/25
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may be that our participants with increased LV EDWT
exhibited myocardial ischemia in endocardial regions due
to undiagnosed CAD. In turn, this unidentified inducible
ischemia could have accounted for their future cardiac
events. Addressing this point could occur with gadolin-
ium enhanced first-pass dobutamine perfusion tech-
niques [20].
Fourth, the presence of increased LV EDWT may portend
a poor prognosis independent of the presence of coronary
arteriosclerosis. Increases in LV EDWT can result from one
or more of several factors including: increased LV after-
load (due in part to increased vascular stiffness, factors
influencing the neuro-hormonal axis (for example eleva-
tions of renin, angiotensin, or aldosterone), or preexisting
genetic abnormalities [21,22]. Also, preclinical hyper-
trophic cardiomyopathy has been described [23]. Each of
these variables in isolation or in combination with the
other variables are associated with adverse cardiac events.
In addition, their influence on the left ventricle promotes
myocyte hypertrophy (often manifest as increased wall
thickness) which is also an independent predictor of car-
diac events [24]. Since we did not measure factors influ-
encing the neuro-hormonal axis or assess genetic factors
in the current study, we cannot comment on the potential
influence of these variables on our outcomes.
The findings of the current study have several important
clinical implications for the management of patients with
chest pain syndromes. First, the absence of dobutamine
induced WMA in individuals with a resting left ventricular
EDWT of ≥12 mm does not forecast the same cardiac
prognosis as for individuals with a LV EDWT <12 mm. In
fact, in the participants in this study with a LVEF >55%
and no inducible LV WMA, the 2-year hard event free sur-
vival was 89%. In a previous study from our group that
included patients referred for dobutamine stress that
exhibited inducible ischemia and a LVEF >40%, the 2-year
event free survival was 84% [5]. In short, in the setting of
resting LV EDWT ≥12 mm and no inducible WMA, one
should be concerned about not only the presence of unde-
tected CAD (as noted by Smart, et al.)[7], but also that
these individuals may have a poor cardiac prognosis rela-
tive to individuals with a wall thickness <12 mm.
Second, further investigation should be considered to risk
stratify patients with a LV EDWT >12 mm but without
inducible WMA during intravenous dobutamine.
Recently, Paetsch, et al [20], has demonstrated the utility
of vasodilator first pass perfusion imaging in order to
identify perfusion defects at the endocardial level associ-
ated with epicardial coronary artery stenoses. Addition-
ally, in the setting of patients with hypertrophied
ventricles or underlying CAD, Kwong et al.[25], and
Moon et al [26], have shown recently that the presence of
Late gadolinium enhancement is associated with fibrosis
and an adverse cardiac prognosis.
Third, it is important to recognize that we did not measure
left ventricular mass in the current study. Thus, those indi-
viduals with eccentric left ventricular hypertrophy, who
may have normal wall thickness, or those with concentric
remodeling, who may or may not have an absolute
increase in wall thickness depending upon their left ven-
tricular cavity size, are not included in the current analy-
ses. For this reason, these data are somewhat preliminary
and further studies that would understand the relation-
ship between left ventricular hypertrophy and the patterns
of hypertrophy and adverse cardiovascular events are war-
ranted.
Fourth, the study was performed using measures of LV
EDWT derived from cine, gradient-echo white blood
imaging techniques. At 1.5 T, this image acquisition strat-
egy often exhibits flow artifacts along the LV endocardial
surface, particularly in apical views when LV systolic func-
tion is reduced. Though this technique has been used in
large 6000 person population studies such as the Multi-
Ethnic Study of Atherosclerosis [27], newer steady-state
free precession cine white blood imaging techniques are
more frequently used clinically. These data suggest similar
studies should be performed that determine the prognos-
tic importance of routine measures of heart size using
steady-state free precession techniques.
Our study has the following limitations. First, according
to previously published criteria from transthoracic
echocardiography, we selected a dichotomous variable of
< or ≥12 mm in LV EDWT as our primary outcome varia-
ble [10]. Abnormal measures of LV EDWT have not been
well established for gradient-echo or steady-state free pre-
cession CMR. These data suggest that future studies, simi-
lar to those performed with echocardiography, are
Table 4: Multivariate predictors of events expressed as hazard 
ratio (± 95% confidence intervals)
Multivariate
Covariate CV Death/MI Any Event
Age (Years) 1.00 (0.97  1.03) 1.05 (0.99  1.10)
Hypertension 1.32 (0.60  2.90) 0.64 (0.17  2.35)
Receiving Statin 1.14 (0.58  2.25) 0.56 (0.19  1.66)
Diabetes 1.79 (0.94  3.49) 2.99 (0.94  9.56)
Male Gender 1.31 (0.69  2.48) 2.88 (0.85  9.72)
Prior CAD or Revasc. 1.74 (0.90  3.37) 1.58 (0.54  4.62)
Smoking 1.19 (0.63  2.25) 1.33 (0.47  3.77)
Wall Thickness ≥ 12 2.34 (1.15  4.74) 4.28 (1.1016.62)
Abbreviations: CAD, coronary artery disease; Revasc., prior coronary 
artery revascularization procedure.Journal of Cardiovascular Magnetic Resonance 2009, 11:25 http://www.jcmr-online.com/content/11/1/25
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warranted to establish prognostic importance of routinely
acquired CMR parameters of wall thickness. Although, the
sample size was not large enough to have good power to
detect moderate size effects, the observed hazard ratios of
6.0 for hard events and 3.0 for any events were large
enough to demonstrate that there is a statistically (and
clinically) significant increased risk of hard or any events
with increased wall thickness.
Second, measures of LV mass using a multi-slice short axis
Simpson's Rule acquisition strategy were not acquired in
the current study. Importantly however, our measures of
LV EDWT are easily acquired and can be reported during
echocardiographic as well as CMR techniques; hence the
clinical applicability of this finding is high. Finally, we are
unable to identify whether there is a threshold of LV
EDWT that confers information regarding cardiac progno-
sis among individuals with different race [28]. The preci-
sion of the magnetic resonance data combined with the
perfect longitudinal follow-up over 7 years allowed us to
draw conclusions from a relatively small sample size, but
the relevance of this measure across individuals of differ-
ent race requires further study.
Conclusion
These data indicate that in those with a LV ejection frac-
tion >55% at rest and no inducible WMA during intrave-
nous dobutamine, a LV EDWT measurement of ≥12 mm
using cine white blood gradient-echo imaging techniques
is associated with adverse cardiac events. Increased LV
wall thickness should be considered a risk factor for car-
diac events in individuals receiving negative reports of
inducible ischemia after dobutamine stress. Additional
prognostic studies of the importance of LV wall thickness
and mass measured with steady-state free precession tech-
niques are warranted.
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